586 related articles for article (PubMed ID: 19363330)
1. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
[TBL] [Abstract][Full Text] [Related]
2. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
4. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
[TBL] [Abstract][Full Text] [Related]
7. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
8. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
9. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
15. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
16. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Hansen AB; Obel N; Nielsen H; Pedersen C; Gerstoft J
HIV Med; 2011 Mar; 12(3):157-65. PubMed ID: 20722752
[TBL] [Abstract][Full Text] [Related]
18. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
19. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
20. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
